Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst

Key Points

• HC Wainwright lowered Spyglass Pharma’s Q3 2026 EPS forecast to a loss of $0.63 per share from its previous estimate of $0.50, following additional forecasts for continued losses through 2027.
• Spyglass reported a Q2 loss of $0.59 per share, missing the consensus estimate by $0.11. Weiss Ratings initiated coverage with a “sell (e)” rating, while the broader analyst consensus remains “Moderate Buy” with a $45 target price.
• Spyglass shares opened at $25.16, with a market capitalization of approximately $841 million; several institutional investors, including Affinity Asset Advisors, recently established positions in the company.

Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Spyglass Pharma in a research report issued to clients and investors on Friday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.63) for the quarter, down from their prior forecast of ($0.50). The consensus estimate for Spyglass Pharma's current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Spyglass Pharma's Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($2.52) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.64) EPS and FY2027 earnings at ($2.57) EPS.

Spyglass Pharma (NASDAQ:SGP - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.11).

Separately, Weiss Ratings assumed coverage on Spyglass Pharma in a research note on Thursday. They set a "sell (e)" rating for the company. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $45.00.

Spyglass Pharma Stock Performance

NASDAQ:SGP opened at $25.16 on Tuesday. The company has a market capitalization of $841.10 million and a P/E ratio of -3.93. Spyglass Pharma has a twelve month low of $17.06 and a twelve month high of $32.44. The stock's fifty day simple moving average is $20.38.

Institutional Investors Weigh In On Spyglass Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SGP. The Manufacturers Life Insurance Company purchased a new stake in Spyglass Pharma in the 1st quarter worth approximately $308,000. Bank of New York Mellon Corp purchased a new stake in Spyglass Pharma during the second quarter worth $533,000. Bank of America Corp DE acquired a new stake in Spyglass Pharma during the first quarter valued at $726,000. Monashee Investment Management LLC purchased a new position in Spyglass Pharma in the first quarter valued at $2,461,000. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of Spyglass Pharma during the 1st quarter worth about $6,478,000.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source